Day 1 – Thursday, September 10, 2026 - ET (Eastern Time, GMT-05:00)
- Nhu Tran - Conference Producer, Informa Connect
- Milagros Blazquez - Director Clinical Trial Transparency & Disclosure Lead, Bristol Myers Squibb
Develop an overview of the most significant regulatory changes in 2025 and 2026 impacting clinical trials disclosure across major jurisdictions
Dive into the MHRA April 2026 changes, EU CTIS post-implementation realities, US registry evolution and emerging market requirements that affect your day-to-day operations
Gain clarity on where regulations are aligning, where they're diverging and how to prioritize compliance efforts in a fragmented global landscape
- Kavita Verma - Senior Trial Transparency Manager, Sanofi
- Lonima Deori - Director, Clinical Transparency, Novo Nordisk
Discover how AI tools support clinical trial transparency activities including document QC, risk‑based anonymization, metadata checks, plain language summary development and content harmonization across jurisdictions
Understand where AI enhances accuracy and efficiency in disclosure workflows and where human oversight remains essential to ensure compliance, patient privacy protection and alignment with global regulatory expectations
Learn practical considerations for adopting AI responsibly including governance models, validation steps and strategies for integrating AI into existing systems without increasing site or team burden
- Ranjita Mishra - Trial Transparency Group Lead, Sanofi
- Navneet Kaur - Senior Manager, Disclosure & Transparency, Gilead Sciences
- Tom Chmielewski - Senior Director, Disclosure & Transparency, Jazz Pharmaceuticals
- Woo Song - Co-Founder & CEO, Xogene
- Andrew Bostjancic - Senior Business Development Manager, Taylor & Francis
Unlock technology-enabled approaches and frameworks to identifying and protecting commercially confidential information across clinical document submissions
Learn how organizations are streamlining CCI redaction workflows to meet tight regulatory deadlines across EU CTR, Health Canada PRCI and EMA Policy 0070
Examine practical considerations for implementing end-to-end CCI solutions while maintaining compliance
- Obaraboye Olude, MBBS, MPH - Clinical Trials Transparency Manager, Privacy Analytics
Examine the growing global expectation for returning clinical trial results and, where appropriate, individual‑level data to participants
Explore ethical, regulatory and operational considerations for returning data in a way that is accurate, understandable and actionable for patients
Share emerging best practices for designing participant‑focused result return strategies that build trust, respect contribution and support long‑term engagement
- Emily Donnelly - Associate Director, Labeling & Disclosures, Sarepta Therapeutics
- Kristi Whiteside - Head of Clinical Trial Transparency Operations, Biogen
Hear directly from patients, caregivers and clinical sites about their experiences accessing and understanding clinical trial information, including what works, what doesn't and what's missing
Explore the gap between what companies create and what patients receive, understand and use when making decisions about trial participation and staying informed throughout the research process
Gain actionable insights on how to design transparency efforts that genuinely serve patient needs rather than just meeting regulatory requirements
- Behtash Bahador - Senior Director, Community Engagement and Partnerships, CISCRP
- Patrick O. Gee, PhD., JLC
- T.J. Sharpe, Patient Engagement Expert
Explore the evolving global privacy landscape including EHDS and DOJ Data Security Program and how these frameworks impact clinical trial data sharing across regions
Learn practical strategies for sharing individual patient data responsibly while mitigating reidentification risks, addressing consent limitations and aligning with diverse jurisdictional privacy requirements
Gain insights governance models, secure data access pathways and best practices for balancing transparency, scientific collaboration and patient privacy in an increasingly regulated environment
- Rebecca Li, PhD - CEO, Vivli
Understand the purpose and scope of EHDS and how it represents a long‑term shift in how clinical trial and health data may be accessed and reused across Europe
Clarify how EHDS differs from existing data‑sharing frameworks, including what is new, what is future‑dated, and what disclosure teams should be tracking now
Explore early implications for global sponsors, including governance readiness, disclosure planning, and how EHDS could influence future transparency and publication expectations
- Barbara Bierer - Faculty Director, Multi-Regional Clinical Trials Center (MRCT)
Address the common organizational challenge of unclear ownership and accountability for anonymization decisions across clinical trial documents and data packages
Explore different governance models including centralized decision-making, cross-functional review committees and hybrid approaches used by leading organizations
Learn how to establish clear roles, responsibilities and escalation pathways for anonymization decisions that balance privacy protection with operational efficiency
- Julie Holtzople - President, Holtzople Consulting
Explore how leading organizations integrate disclosure considerations throughout the entire clinical trial lifecycle, from protocol development through results posting and archiving
Examine the operational challenges when disclosure teams are brought in too late and the downstream consequences of studies not designed with transparency in mind
Learn practical frameworks for embedding disclosure checkpoints at key study milestones to prevent compliance bottlenecks, reduce rework, and improve data quality
- Nicholas Segerson - Senior Medical Writer, Merck
- Jacob Somerson - Associate Director, Medical Writing, Travere Therapeutics
- Optimizing disclosure operations: Streamlining end‑to‑end clinical trial disclosure through integrated, cross‑functional processes
Technology and AI in action: Using automation and AI to reduce manual work, standardize workflows, and improve efficiency
Lessons from real implementations: Practical insights from delivered process improvement and AI initiatives that drove measurable impact
- Michelle Clausen - Senior Director, Clinical Disclosure and Expanded Access, Pfizer
- Belkis Karakas - Clinical Trial Disclosure Operations Lead, Pfizer
Explore challenges in ensuring consistency between clinical trial registries like ClinicalTrials.gov and peer-reviewed publications
Examine discrepancies in trial design, outcome measures, and adverse event reporting, and their impact on patient trust and secondary research
Gain insights into practical strategies for harmonizing data reporting, fostering transparency, and building credibility across clinical trial platforms
- Shalini Dwivedi - Head of Medical Writing and Clinical Trial Transparency, Krystelis Ltd.
